FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 318:1499-1507 June 9, 1988 Number 23 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a randomized trial in seven Australian hospitals of the efficacy and safety of three immunosuppressive regimens after first transplantation of a cadaver kidney: long-term cyclosporine, short-term (three months) cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. Patients assigned to long-term cyclosporine (n = 138) or short-term cyclosporine followed by azathioprine and prednisolone (n = 141) had similar actuarial 12-month survival (98.4 vs. 96.4 percent) and graft survival (83.9 vs. 82.1 percent). Patients assigned to receive only azathioprine and prednisolone (n = 138), with optional use of antithymocyte globulin, had a significantly poorer survival rate (91.3 percent, P = 0.015) because of deaths from cardiac causes and infection, but their graft survival of 76.0 percent (P = 0.31) did not differ significantly from that of either group receiving cyclosporine. After the switch from cyclosporine to azathioprine and prednisolone, 15 percent of patients had reversible rejection episodes, but the frequency of rejection and graft loss did not differ from that in the long-term cyclosporine group. After the change to azathioprine and prednisolone, serum creatinine levels declined in nearly all patients, so that after three months they were comparable to those in the group receiving azathioprine and prednisolone only, and significantly lower than those in the group receiving long-term cyclosporine therapy (P less than 0.003). We conclude that the two cyclosporine regimens result in comparable patient and graft survival, but that changing to azathioprine and prednisolone at three months improves graft function.

Source Information

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

This article has been cited by other articles:

• Chapman, J. R., Nankivell, B. J. (2006). Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?. Nephrol Dial Transplant 21: 2060-2063 [Full Text]  
• Schnuelle, P., van der Heide, J. H., Tegzess, A., Verburgh, C. A., Paul, L. C., van der Woude, F. J., de Fijter, J. W. (2002). Open Randomized Trial Comparing Early Withdrawal of either Cyclosporine or Mycophenolate Mofetil in Stable Renal Transplant Recipients Initially Treated with a Triple Drug Regimen. J. Am. Soc. Nephrol. 13: 536-543 [Abstract] [Full Text]  
• KASISKE, B. L., CHAKKERA, H. A., LOUIS, T. A., MA, J. Z. (2000). A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. J. Am. Soc. Nephrol. 11: 1910-1917 [Abstract] [Full Text]